Rocket Pharmaceuticals Inc (RCKT)

$3.05 -0.12 (-3.79%)
Market Cap 330.08M
Revenue (ttm) 0.00
Net Income (ttm) -258.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,130,600
Avg Vol 2,471,830
Day's Range N/A - N/A
Shares Out 108.22M
Stochastic %K 8%
Beta 0.70
Analysts Sell
Price Target $7.81

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
radiostock
radiostock Nov. 17 at 12:59 AM
$RCKT @mailman1961 Throw some light here. How low will this go? Worried about XBI cooling and tax loss season.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:56 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.05 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
darntootin
darntootin Nov. 16 at 10:40 PM
$RCKT Credibility and Investor Confidence: The involvement of two highly respected figures with proven track records at major pharma companies like Pfizer and an innovative leader like Spark Therapeutics enhances Rocket's credibility in the eyes of investors, partners, and regulators. It suggests that industry veterans believe in the science and potential of Rocket's pipeline.
0 · Reply
darntootin
darntootin Nov. 16 at 10:40 PM
$RCKT Scientific and Strategic Leadership: Mikael Dolsten's background as Pfizer's former R&D chief for over a decade brings high-level strategic insight, extensive experience in drug development, and a strong network within the global pharmaceutical and biotech community. His role on the board provides guidance on pipeline management and overall company strategy. Operational and Manufacturing Expertise: Chris Stevens' hands-on experience in manufacturing and commercializing the first FDA-approved gene therapy (Luxturna) provides Rocket with invaluable operational knowledge. He ensures the company is capable of navigating the complex manufacturing and supply chain hurdles that often sideline smaller biotechs.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 6:06 AM
💎 LiquidTheta® Live Actionable Trade Asset: $RCKT Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.50- $0.62 Scale out: $1.96-$3.36 Profit Potential : 248% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:59 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.05 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Grenville1
Grenville1 Nov. 15 at 5:30 PM
$RCKT Very good point. I asked Grok what it thought and it agrees: "The plausible mechanism pathway is highly relevant to Rocket (NASDAQ: RCKT) as it directly aligns with the company's focus on AAV/LVV gene therapies for ultrarare, genetically defined diseases—precisely the scenarios the FDA aims to accelerate."
0 · Reply
Orlandotrader
Orlandotrader Nov. 15 at 4:38 PM
$RCKT Acts terrible. Next buy for me at 2.75$
0 · Reply
oaksapollo
oaksapollo Nov. 15 at 1:34 AM
$RCKT How is this not rallying on this news? Seems like every Rocket program could seek approval under the plausible mechanism pathway. https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/
0 · Reply
pjapak
pjapak Nov. 14 at 9:15 PM
$RCKT Head and shoulder is taking it down. I hope this was bottom but not sure with taxloss selling starting.
0 · Reply
Latest News on RCKT
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 4:00 PM EST - 10 days ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Oct 14, 2025, 2:27 PM EDT - 4 weeks ago

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2025, 4:00 PM EDT - 5 weeks ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 6 weeks ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:36 PM EDT - 2 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 3 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 9:31 AM EDT - 3 months ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 3 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 3 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 3 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 6:29 PM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 29, 2025, 10:26 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 25, 2025, 3:02 PM EDT - 4 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 4:02 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 11, 2025, 10:25 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 4 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jul 7, 2025, 9:00 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

radiostock
radiostock Nov. 17 at 12:59 AM
$RCKT @mailman1961 Throw some light here. How low will this go? Worried about XBI cooling and tax loss season.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:56 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.05 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
darntootin
darntootin Nov. 16 at 10:40 PM
$RCKT Credibility and Investor Confidence: The involvement of two highly respected figures with proven track records at major pharma companies like Pfizer and an innovative leader like Spark Therapeutics enhances Rocket's credibility in the eyes of investors, partners, and regulators. It suggests that industry veterans believe in the science and potential of Rocket's pipeline.
0 · Reply
darntootin
darntootin Nov. 16 at 10:40 PM
$RCKT Scientific and Strategic Leadership: Mikael Dolsten's background as Pfizer's former R&D chief for over a decade brings high-level strategic insight, extensive experience in drug development, and a strong network within the global pharmaceutical and biotech community. His role on the board provides guidance on pipeline management and overall company strategy. Operational and Manufacturing Expertise: Chris Stevens' hands-on experience in manufacturing and commercializing the first FDA-approved gene therapy (Luxturna) provides Rocket with invaluable operational knowledge. He ensures the company is capable of navigating the complex manufacturing and supply chain hurdles that often sideline smaller biotechs.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 6:06 AM
💎 LiquidTheta® Live Actionable Trade Asset: $RCKT Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.50- $0.62 Scale out: $1.96-$3.36 Profit Potential : 248% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:59 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.05 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Grenville1
Grenville1 Nov. 15 at 5:30 PM
$RCKT Very good point. I asked Grok what it thought and it agrees: "The plausible mechanism pathway is highly relevant to Rocket (NASDAQ: RCKT) as it directly aligns with the company's focus on AAV/LVV gene therapies for ultrarare, genetically defined diseases—precisely the scenarios the FDA aims to accelerate."
0 · Reply
Orlandotrader
Orlandotrader Nov. 15 at 4:38 PM
$RCKT Acts terrible. Next buy for me at 2.75$
0 · Reply
oaksapollo
oaksapollo Nov. 15 at 1:34 AM
$RCKT How is this not rallying on this news? Seems like every Rocket program could seek approval under the plausible mechanism pathway. https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/
0 · Reply
pjapak
pjapak Nov. 14 at 9:15 PM
$RCKT Head and shoulder is taking it down. I hope this was bottom but not sure with taxloss selling starting.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:42 PM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.06 Profit Margin: +109% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Drashkawisha
Drashkawisha Nov. 14 at 12:13 PM
$RCKT The Case: A "Phoenix" play following its PDUFA miss. Fact 1: The CRL for Kresladi (LAD-I) was based on CMC/manufacturing issues. The FDA did not cite issues with clinical efficacy or safety. Fact 2: The thesis rests on a successful resubmission and the strength of the broader gene therapy pipeline.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 8:01 AM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.04 Profit Margin: +42% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:51 AM
Hedge Alert Live - Protect Your Portfolio Contract: $RCKT $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.10 Exit Price Target: $0.04 Profit Margin: +42% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
CaptObvious2014
CaptObvious2014 Nov. 13 at 5:15 PM
$RCKT locked profit. $ on sidelines
0 · Reply
darntootin
darntootin Nov. 13 at 1:42 AM
$RCKT In mid July we had a hold on the trial for dannons disease after a death in the trial and no resolution to the CRL the price was 3.33 as of today the hold has been lifted and we have resolution of the CRL we closed at 3.32 nobody will ever convince me all that great news is worth a penny this stock is very undervalued I will be buying more gl
0 · Reply
GSTX7
GSTX7 Nov. 12 at 11:16 PM
$RCKT Relax and buy at these gift prices. Only a matter of time...
0 · Reply
pjapak
pjapak Nov. 12 at 5:12 PM
$RCKT Some fund loading!
0 · Reply
HarveySpecter20
HarveySpecter20 Nov. 11 at 10:19 PM
$RCKT bought a starter here, planning to add more.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 11 at 12:53 AM
$RCKT WILL CHANGE THIS 3.10 (*3.23 USE THE REMAINDER OF YOUR CHART BACKWARDS FOR STOCK COMING DOWN FROM ABOVE 19
1 · Reply
pjapak
pjapak Nov. 10 at 6:02 PM
$RCKT Time to announce some fireside chat and discuss commercialization plans or insider buying at this level to boost.
0 · Reply
Drashkawisha
Drashkawisha Nov. 10 at 2:13 PM
$RCKT KRESLADI approval in the bag. Now the game shifts from regulatory binary risk to commercial execution. Long-term hold as they build out the launch and advance the rest of the rare disease pipeline. The validation is already there.
2 · Reply